MedTrace Logo

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

NCT00516438 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-12-08

No results posted yet for this study

Summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours

Conditions

  • Malignant Solid Tumors

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

Topotecan

intravenous infusion

Sponsors & Collaborators

  • KuDOS Pharmaceuticals Limited

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • James Cassidy · Beaston Oncology Centre, Glasgow, UK

  • James Carmichael, BSc MBChB MD FRCP · KuDOS Pharmaceutical Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-03-31
Completion
2009-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516438 on ClinicalTrials.gov